Septic Shock – Drugs In Development, 2024
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Septic Shock – Drugs In Development, 2024 report and make more profitable business decisions.
Septic shock, the most severe complication of sepsis, occurs in response to an inciting agent, which causes both pro-inflammatory and anti-inflammatory immune system activation. It involves very low blood pressure, an altered mental state, and organ dysfunction. Sepsis syndromes are often caused by multidrug-resistant bacterial strains such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), among others.
The Septic Shock drugs in development market research report provide comprehensive information on the therapeutics under development for Septic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Septic Shock and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
Quick View – Septic Shock | Key Targets |
|
|
Key Mechanisms of Action |
|
||
Key Routes of Administration |
|
||
Key Molecule Types |
|
||
Major Companies |
|
Scope
- Therapeutics in Development: Covering 21 molecules, with 18 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Septic Shock therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Septic Shock pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Septic Shock treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Adrenomed AGAptahem AB
Brandenburg Antiinfektiva GmbH
Center for Genetic Engineering and Biotechnology
Endpoint Health Inc
Hibernaid Inc
InflaRx NV
Inotrem SA
LifeArc
Matisse Pharmaceuticals BV
Modus Therapeutics AB
Noxopharm Ltd
Peptinov SAS
Pharmazz Inc
Radikal Therapeutics Inc
Sanofi
StemInov SAS
University of Missouri
US Army Medical Research & Materiel Command
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Septic Shock reports![](https://www.globaldata.com/store/wp-content/uploads/sites/2/blue_1bg2.webp)
![](https://www.globaldata.com/store/wp-content/uploads/sites/2/blue_1bg2.webp)
![](https://www.globaldata.com/store/wp-content/uploads/sites/2/blue_1bg2.webp)